Selective O-GlcNAcase Inhibitors for Tau Hyperphosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors for blocking the function of mammalian glycosidases, including O-GlcNAcase, are non-selective and affect multiple enzymes, leading to complex phenotypes and limited therapeutic efficacy in treating diseases like Alzheimer's and tauopathies.
Innovation Solution
Development of potent and selective O-GlcNAcase inhibitors, represented by specific structural formulas, which target the enzyme responsible for removing O-GlcNAc from tau proteins, thereby regulating hyperphosphorylation and associated neurodegenerative processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective inhibitors are used to block O-GlcNAcase function, then inhibition potency is achieved, but selectivity is lost and multiple enzymes are affected
Solution Approach 1:
The patent applies local quality by introducing specific structural features at particular positions of the inhibitor molecule. The core structure contains defined substituents at specific locations (e.g., R1-R6 positions) that are optimized to interact with unique residues in the O-GlcNAcase active site, thereby achieving selective inhibition while maintaining potency
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the inhibitor molecules, including substituent types, ring sizes, and spatial configurations. These parameter optimizations enable differentiation between O-GlcNAcase and other glycosidases, achieving both potency and selectivity through precise molecular design
2Reliability
If existing glycosidase inhibitors are used, then enzyme function is blocked, but therapeutic efficacy is limited due to complex phenotypes from multiple enzyme inhibition
Solution Approach 1:
The patent applies the extraction principle by isolating the specific inhibitory activity against O-GlcNAcase from the broader glycosidase inhibition profile. Through careful molecular design, the inhibitors selectively target O-GlcNAcase while excluding other glycosidases, thereby extracting the desired therapeutic effect and eliminating complex phenotypes associated with non-selective inhibition
3Reliability
If selective O-GlcNAcase inhibitors are developed, then tau hyperphosphorylation is reduced, but compound specificity and synthesis complexity increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: a core heterocyclic structure, specific substituent groups at defined positions, and stereochemical elements. This modular design achieves the necessary complexity for selective tau hyperphosphorylation reduction while maintaining rational design principles that facilitate systematic optimization
Data Source
AI summary
Described herein are compounds represented by formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, m, n, and p are as defined herein.